Rova-T: the story of AbbVie’s multi-billion dollar failure

Rova-T: the story of AbbVie’s multi-billion dollar failure

Source: 
Pharmaforum
snippet: 

Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T.

Rova-T was supposed to be the cancer drug that would bolster AbbVie’s revenues as revenues from the $20bn a year Humira (adalimumab) begin to dry up thanks to cheaper competitors.